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Pegeneration Gaps
bservations on Stem Cells and Cardiac Repair
harles E. Murry, MD, PHD, Hans Reinecke, PHD, Lil M. Pabon, PHD
eattle, Washington
Substantial evidence indicates that cell transplantation can improve function of the infarcted
heart. A surprisingly wide range of non-myogenic cell types improves ventricular function,
suggesting that benefit may result in part from mechanisms that are distinct from true
myocardial regeneration. While clinical trials explore cells derived from skeletal muscle and
bone marrow, basic researchers are investigating sources of new cardiomyocytes, such as
resident myocardial progenitors and embryonic stem cells. In this commentary, we briefly
review the evolution of cell-based cardiac repair, discuss the current state of clinical research,
and offer some thoughts on how newcomers can critically evaluate this emerging
field. (J Am Coll Cardiol 2006;47:1777–85) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.002Cardiology Foundation
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item cells are the building blocks through which tissues are
eveloped and maintained. We and many other groups
redict that stem cells will prove tremendously useful in
linical medicine. Possible uses include systems for high-
hroughput drug screens, as in vitro models of disease and,
ventually, in treating diseases associated with cell defi-
iency. As one of the least regenerative organs in the body,
he heart stands to benefit greatly from addition of new
arenchymal cells. Cardiovascular researchers have risen to
his challenge and, as a result, cardiac repair is arguably the
ost advanced program in the emerging field of regenera-
ive medicine. Progress in this field has been rapid, from
umble beginnings with committed skeletal (1–3) or cardiac
uscle cells (4–6), moving to multipotent adult stem cells
7–9) and, most recently, to embryonic stem cells (10–13).
In this brief commentary, we review some important
ecent developments in stem cell-based tissue repair. (Read-
rs wishing additional basic and clinical information are
irected to several recent in-depth reviews [14–16] on the
eld.) Like other areas involving stem cell-based regeneration,
he field of cardiac repair has its share of controversies. These
ill also be touched upon, with an aim of separating experi-
ental observation, on which there is much agreement, from
nterpretation, which varies widely at the moment.
VERY CELL TYPE SEEMS
O IMPROVE CARDIAC FUNCTION
few calculations are helpful in assessing the scope of
egenerating a human myocardial infarct. Myocardium con-
ains approximately 20 million cardiomyocytes per gram of
issue (17). The average left ventricle is approximately 200 g
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005, accepted December 19, 2005.nd therefore contains approximately 4 billion cardiomyocytes.
o cause heart failure, an infarct needs to kill approximately
5% of the ventricle (for comparison, infarcting 40% of the
entricle results in acute cardiogenic shock) (18). Therefore,
he myocyte deficit in infarction-induced heart failure is on
he order of one billion cardiomyocytes. True cardiac
egeneration would therefore require restoring approxi-
ately one billion cardiomyocytes and ensuring their syn-
hronous contraction via electromechanical junctions with
ost myocardium.
Although today’s technology clearly cannot achieve this
oal of true regeneration, we are fortunate that substantial
hysiological benefit (repair) currently can be derived from
ransplanting cells into the infarcted heart. What is most
urprising, however, is that almost every cell type tested
eems equipotent: benefit is derived from cardiomyocytes
6,19,20), skeletal myoblasts (21–23), smooth muscle cells
24), fibroblasts (25), endothelial progenitors (26), mesen-
hymal stem cells (27), hematopoietic stem cells (7,28),
ther marrow populations (29), resident myocardial progen-
tors (30), and embryonic stem cells (13). Consequently, the
echanism underlying the benefit has been difficult to pin
own. Although most studies sought to restore systolic
unction to an infarcted region, it seems clear that most of
he benefit results from something other than graft cells
eating in synchrony with host myocardium. One of these
nanticipated benefits is improvement of the infarct’s pas-
ive mechanical properties and subsequent amelioration of
entricular remodeling (23). Improved passive mechanics
ay result in part from a mechanical buttressing of the
nfarcted wall by the transplanted cells. A second benefit is
he so-called paracrine effect, which refers to the production
f local signaling molecules that may improve perfusion to
hronically ischemic tissue (31) or promote survival of
enuous cardiomyocytes (26). Indeed, Gnecchi et al. (32)
ecently reported that most of the benefit of mesenchymal
tem cell transplantation in the heart could be reproduced by
njecting the cell-free supernatant recovered from mesen-
hymal stem cell cultures.
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Stem Cells and Cardiac Repair May 2, 2006:1777–85Improvement of the heart’s function by so many cell
ypes, most of which are non-cardiogenic, is at once frustrating
nd encouraging. Frustration arises because, despite much
ard work, no group has developed reproducible techniques
hat generate substantial amounts of new, beating myocar-
ium in the infarcted heart. However, it is encouraging that
ellular therapies, even with current limitations, can signif-
cantly improve function of the infarcted heart. These
herapies open the door to testing existing cardiac repair
trategies in the clinic while basic scientists work on
eciphering mechanisms that will lead to bona-fide cardiac
egeneration.
ULTIPLE CELL TYPES
OME TO THE INJURED HEART
t has been known for many decades that myocardial
nfarction is an inflammatory disease, which results first in
he homing of neutrophils and later monocytes from the
irculation (33). We have appreciated only recently, how-
ver, that marrow-derived progenitor cells circulate and
ome to injured tissues similarly to leukocytes, where they
ontribute to formation of new tissues (34,35). A “natural”
uman experiment occurs when female hearts are trans-
lanted into male patients. This procedure permits one to
se Y chromosome in situ hybridization to track the male
ells in the female allografts, coupled with immunostaining
o define the identity these cells have acquired (similar
rocesses likely occur outside this specialized setting but are
ore difficult to track). Multiple groups have shown that
ost components of myocardium can be derived from
xtracardiac progenitors, but the frequency of repopulation
aries widely by cell type (36–41). In our studies (37),
ndothelial cells were the most commonly derived from
rogenitors, averaging 24%. These were followed by peri-
eural Schwann cells at 11% and coronary smooth muscle
ells at 3%. Cardiomyocytes, unfortunately, were only de-
ived rarely from circulating progenitors, averaging 0.04%
36). The likely source of such cells is the bone marrow, as
eb et al. (40) has shown similar myocardial repopulation in
atients with male-to-female bone marrow transplants. The
esson we draw from such experiments is that circulating
rogenitor cells are promising for revascularization of isch-
mic tissues, but they are much less promising for remus-
ularization of infarcts.
In addition to tracking endogenous cells, several exog-
nously administered cell populations have been shown to
Abbreviations and Acronyms
EGFP  enhanced green fluorescent protein
ESC  embryonic stem cell
LacZ  beta-galactosidase
Sca  stem cell antigen
SDF  stromal-derived factorome to the injured heart after intravenous injection, including nndothelial progenitors isolated from blood or marrow
26,42), mesenchymal stem cells from the marrow (35,43),
nd stem cell antigen (Sca)-1–positive cells from the myo-
ardium (44). Indeed, one of the big surprises from work
ith adult stem cells is how many have the ability to home
o injured tissues. This discovery has led to a search for
actors that mediate mobilization and homing. The cytokine
tromal-derived factor (SDF)-1 and its cognate receptor
XCR4 have emerged as important players in this regard.
ctivation of hypoxia-induced transcription factors induces
schemic tissues to produce SDF-1 (45), and SDF-1 appears
o mediate homing of endothelial progenitors and other
ells to the acute infarct (46). Manipulating this pathway
ppears promising for control of cell homing to the heart. A
linical trial of intravenously administered mesenchymal
tem cells in acute myocardial infarction recently has been
nitiated by scientists from Johns Hopkins University and
siris Therapeutics (47).
DULT STEM
ELL TRANSDIFFERENTIATION:
HE RISE (AND PARTIAL FALL)
ransdifferentiation can be defined simply as the acquisition
f an unexpected phenotype in a cellular lineage. Hence,
hen a hematopoietic stem cell gives rise to an erythrocyte
r granulocyte, this is normal, expected differentiation. If
he same hematopoietic stem cell gives rise to a cardiomy-
cyte, this is unexpected and therefore qualifies as transdif-
erentiation. Even this simple definition has two critical
lements, however: cell lineage and cell phenotype. The
mprecise use of these terms often leads to confusion. Cell
ineage strictly refers to a genetic line of descent, telling us
he ancestry of a cell in question. Lineage does not specify
hat specialized features a cell may have. Conversely,
henotype refers to specific cellular features at the time of
tudy, such as gene expression patterns or physiological
unction, and it does not imply where the cell came from. It
s critical that lineage and phenotype markers be shown to
ntersect in the same cell. Errors associated with these
arameters, or their colocalization, likely explain much of
he current controversy in stem cell research.
The late 1990s and first few years of this decade were
arked by dramatic reports of transdifferentiation in mul-
iple organ systems. Examples included marrow ¡ skeletal
uscle (48), marrow/blood ¡ endothelium (49,50), neural
tem cells ¡ blood (51), skeletal muscle ¡ blood (52),
arrow ¡ lung (53), marrow ¡ brain (54,55), marrow ¡
iver (56), and marrow¡ heart (7). Indeed, it seemed for a
hile that the rules of development did not apply to adult
tem cells and that simply placing these cells into new
nvironments was sufficient to induce them to acquire the
henotype of their surrounding tissue.
After a few years, however, several of these conclusions
ere shown to result not from transdifferentiation but from
ovel processes not known to occur at the time of the initial
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May 2, 2006:1777–85 Stem Cells and Cardiac Repaireport. For example, formation of blood from skeletal
uscle turned out to result from “ectopic” hematopoietic
tem cells that unexpectedly resided in skeletal muscle,
ather than conversion of muscle-specific stem cells into
lood (57). Formation of liver from marrow resulted from
he fusion of blood cells with hepatocytes, and subsequent
eprogramming of the leukocyte nucleus to a hepatic phe-
otype (58,59). Other observations were not reproducible
hen subsequently attempted or are suspected to result from
xperimental artifact. For example, formation of blood cells
rom neural stem cells could not be reproduced by another
aboratory despite exhaustive effort (60). Additionally, the
ostulated formation of pulmonary epithelium from marrow
as recently been suggested to be an artifact related to
utofluorescence or close approximation of marrow-derived
eukocytes and lung epithelium (61,62).
O HEMATOPOIETIC STEM CELLS
RANSDIFFERENTIATE INTO CARDIOMYOCYTES?
f particular relevance to the cardiovascular community was
he hypothesis that bone marrow cells can give rise to new
ardiomyocytes. A provocative study from Orlic et al. (7)
uggested that directly injecting hematopoietic stem cells
esulted in extensive myocardial regeneration. These authors
ook bone marrow from mice expressing enhanced green
uorescent protein (EGFP), depleted the differentiated
ells, sorted the remainder for expression of the stem cell
arker c-kit, and then injected them into acutely ischemic
yocardium. They reported that nine days after injection,
egenerating myocardium derived from the donor marrow
ccupied the majority of the infarct region. Further, mice
eceiving stem cell injection showed reduced ventricular
ilation and increased fractional shortening by echocardi-
graphy. This article generated tremendous excitement in
oth the basic and clinical research communities.
To understand the mechanism through which marrow
ells transdifferentiated into cardiomyocytes, our group,
orking in collaboration with Loren Field’s group, devised
genetic screen using cardiac-restricted and ubiquitously
xpressed promoters (63). We isolated hematopoietic stem
ells from transgenic mice wherein the cardiac-specific alpha-
yosin heavy-chain promoter drove expression of nuclear-
argeted beta-galactosidase (LacZ). In these transgenic mice,
ardiomyocytes express LacZ in the nucleus, which can be
dentified by a sensitive histochemical stain, but all other
ells in the body (including the marrow) are LacZ-negative.
ematopoietic stem cells were isolated according to the
rotocol of Orlic and Anversa and injected into acutely
schemic myocardium of wild-type (non-transgenic) mice.
ransdifferentiation into cardiomyocytes would be accom-
anied by activation of the cardiac-specific transgene,
hereby using a single marker to track both the donor
ineage and the cardiac phenotype. Despite the use of an
ssay capable of detecting a single LacZ-positive nucleus in
wild-type heart, we were unable to detect a single pransdifferentiation event in 42 infarcted hearts. Variations
n the myocardial status (cautery injury, isoproterenol-
nduced injury, normal myocardium) and different strategies
or stem cell isolation also failed to yield a single transdif-
erentiation event in another 66 animals. To rule out
rtifacts associated with our specific transgene, we trans-
lanted hematopoietic stem cells from an additional
ardiac-specific transgenic line (alpha-myosin heavy chain/
GFP) and mice ubiquitously expressing EGFP from the
hicken beta-actin promoter. None of these 37 additional
nimals showed evidence for cardiac transdifferentiation.
inally, we compared sarcomeric actin and myosin expres-
ion patterns in mice receiving stem cell transplants to those
eceiving sham injections. There was no difference in the
istribution of actin-positive or myosin-positive cells, indi-
ating that significant regeneration did not occur. It should
e emphasized that the grafted cells were readily identified
n the injured hearts. They were small, round, myosin-
egative and morphologically consistent with leukocytes.
Two other groups reported similar findings around the
ame time. Balsam et al. (28) found that hematopoietic stem
ells did not transdifferentiate into cardiomyocytes, and they
lso showed that these cells instead acquired a leukocyte
predominantly granulocyte) phenotype within the infarct.
ygren et al. (64) reported that hematopoietic stem cell
ormed almost exclusively leukocytes within the infarct,
ith no activation of cardiac genes in the transplanted cells.
hey also showed that mobilization of marrow stem cells
ith cytokines did not result in formation of new cardio-
yocytes, although endogenously derived circulating cells
ere noted to fuse with host cardiomyocytes. The basis for
he discrepant findings among laboratories has not yet been
iscovered. An exchange of experimental samples among
he different groups seems like a reasonable step toward
esolving the differences.
In any case, a very large body of evidence leads us to
onclude that there is no significant cardiac differentiation
fter direct injection of hematopoietic stem cells. A few
irculating cells have been documented to fuse with host
ardiomyocytes (64,65), giving rise to hybrid cells, but these
re too few to influence contractile function. One implica-
ion of this work is that clinical trials of bone marrow for
ardiac repair are unlikely to generate significant numbers of
ew cardiomyocytes. It remains quite possible, however,
hat marrow cells could influence remodeling of the ventri-
le by improving the connective tissue framework or pro-
ote angiogenesis to chronically ischemic regions.
ESIDENT MYOCARDIAL PROGENITORS
n recent years, several groups have reported the isolation of
ardiac stem cells, also termed cardiac progenitor cells, from
at, mouse, dog, and human myocardium. In most studies,
he isolation is based on the absence of cardiomyocyte,
mooth muscle or endothelial markers and the presence of
rimitive cell markers. Examples include cells expressing the
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Stem Cells and Cardiac Repair May 2, 2006:1777–85eceptor for stem cell factor (c-kit) (66), cells expressing
ca-1 but not expressing c-kit (44), or cells expressing the
ransport protein Abcg2 (so-called “side population”),
hich are low in c-kit (67) but have been reported to express
ca-1 (68). Another study has simply used the ability of cells
solated from murine and human myocardium to form
elf-adherent clusters termed “cardiospheres” (in analogy to
eurospheres formed by neural stem cells) in vitro (69).
Beltrami et al. (66) first isolated c-kit cells from adult
yocardium of the rat. A histological analysis revealed that
hese cells were distributed in small clusters in the interstices
etween cardiomyocytes throughout the ventricular and
trial myocardium with a higher density in the atria and the
entricular apex. The cardiac c-kit cells were self-renewing,
lonogenic, and multipotent, giving rise to three different
ardiogenic cell phenotypes, that is, cardiomyocytes, endothe-
ial cells, and smooth muscle cells and after direct injection
egenerated the infarcted rat hearts. These cells have recently
een reported to traverse the vascular barrier and participate in
egeneration after intracoronary injection (30).
Just a month after the discovery of c-kit cardiac stem
ells, Schneider’s group reported the existence of adult
ouse heart-derived cardiac progenitor cells expressing
ca-1 (44). These cells initially expressed no cardiac-specific
enes, but a small percentage activated cardiac genes (but
id not beat) in response to DNA demethylation with
=-azacytidine. In vivo, the Sca-1 cells homed to injured
yocardium after ischemia/reperfusion. Using Cre recom-
inase techniques, the apparent cardiac differentiation was
hown to be due to fusion in approximately 50% of cases.
hortly afterward, Matsuura et al. (70) reported isolation of
ca-1 cells from adult murine hearts. These cells differ-
ntiated into beating cardiomyocytes when treated with
xytocin (yielding 1% beaters), whereas in their hands
=-azacytidine failed to induce cardiac differentiation.
Another cardiac-derived subpopulation with progenitor
otential has been studied by the groups of Martin et al.
67) and Pfister et al. (68). This rare population was isolated
rom mouse hearts based on their ability to exclude Hoechst
3342 dye, so-called side population cells, and the authors
how that the transport protein Abcg2 confers the side
opulation cell phenotype. These cells, which are present
hroughout cardiac development and in the adult heart, also
xpress Sca-1 (but are c-kitlow) and appear capable of
ifferentiation into cardiomyocytes after coculture with rat
ardiomyocytes.
The most recent addition to the burgeoning field of resident
ardiac progenitors is cells expressing the homeobox gene
slet-1 (isl-1). During development, isl-1 cells contribute to
ormation of the outflow tract, the atria and the right ventricle,
hich develop from the “secondary heart field” (71). Laugwitz
t al. (72) showed that a population of isl1 cells persists in
eonatal mouse hearts, which express the cardiac transcription
actors Nkx2.5 and GATA4, but not Sca-1, CD31, or c-kit.
he isolated progenitor cells demonstrate both self-renewal
nd maintain the ability to differentiate into functional cardi- hmyocytes in vitro and in vivo. However, isl-1 cells have only
een isolated from neonatal animals, and their existence or
otential in older adults, where most infarcts occur, is currently
nknown.
Taken collectively, these data argue that the postnatal
eart has one or more populations of resident progenitor
ells, which under some circumstances, can be induced to
orm new cardiomyocytes. The role such cells play in normal
ardiac homeostasis or response to injury is not clear at
resent. Most scientists find it surprising that four non-
verlapping populations of progenitor cells reside in a tissue
hat repairs itself so poorly after infarction. However, other
issues that are known to have stem cells, such as the gut or
rain, also respond poorly to infarction, and therefore failure
o regenerate after injury should not be equated with the
bsence of stem cells. It is possible that resident progenitors
re involved in a much-slower myocyte turnover, replacing
ccasional cell dropout but incapable of regenerating large
njuries like an infarct. Without doubt, a multipotent
ardiac stem cell would be a welcome candidate for cardiac
epair. To be of clinical use, one would need either to
ctivate the proliferation of endogenous progenitors and
romote their migration to the site of injury, or isolate these
rogenitors, expand them sufficiently without sacrificing
otential, and reintroduce them into the injured heart.
urrently, not even the researchers from the best laborato-
ies know how to do this with human cells, but reports exist
hat describe clonogenic expansion while preserving the
unctionality of cardiac stem cells from mouse, rat, and dog.
or this area to move forward, it will be important for each
andidate population to be confirmed by independent
roups and to learn what their endogenous roles are.
MBRYONIC STEM CELLS
ultiple groups have shown that cardiomyocytes can be
eliably obtained from embryonic stem cells (ESCs), derived
rom the inner cell mass of preimplantation mouse and
uman embryos (reviewed in reference 73). Embryonic stem
ell-derived cardiomyocytes express cardiac molecular mark-
rs, including Nkx2.5, GATA4, sarcomeric myosin heavy
hain, and cardiac troponin I. Ultrastructural studies show-
ng myofibrillar assembly and formation of intercalated
isks indicate potential for a high degree of developmental
aturity (74). Electromechanical coupling and electro-
hysiologic specialization also have been observed (75,76).
he versatility of ESCs is their greatest asset, but it also
akes the isolation of the cells of interest more challenging.
urrent protocols yield cardiomyocytes in sufficient quan-
ities for most basic research needs. However, a limitation of
he use of ESC for therapeutic purposes is the inefficiency
ith which cardiomyocytes are generated (typically 1% of a
ifferentiating culture). Strategies based on developmental
aradigms have used directed differentiation to increase
ardiogenesis (77). These methods have had some success;
owever, not surprisingly, no one has been able to fully
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May 2, 2006:1777–85 Stem Cells and Cardiac Repairecapitulate the complex mixture of cardiogenic factors and
nvironmental cues that efficiently induce cardiomyogenesis
uring embryonic development.
Other groups have suggested that transplantation of
ndifferentiated ESCs into the heart provides the appropri-
te signals to induce cardiomyocyte differentiation that
esults in an improvement of contractile function (78,79).
s appealing as this approach might be, subsequent studies,
ncluding our own, have shown that this method leads to
he formation of teratomas (a tumor type composed of cells
erived from all three embryonic germ layers) (80,81).
eratomas are arguably the greatest risk associated with
SC-based therapy. In fact, recent studies have shown that
he formation of teratomas can counteract the benefit
rovided by the intended cellular therapy (82,83). There-
ore, predifferentiation and purity are prerequisites to the
pplication of cell-based therapies using ESC-derived cells.
n an effort to increase purity, Klug et al. (84) selected
ardiomyocytes using a cardiac-restricted promoter to drive
he expression of a neomycin resistance gene, which allowed
or the isolation of a population containing 99.6% ESC-
erived cardiomyocytes. Other groups have enriched for
ardiomyocytes using restricted promoters in combination
ith fluorescence-based cell sorting. The promise of the
enetic selection strategy has been further validated by
calability studies (85).
Increasing the number of cells through mitogenic stim-
lation is another approach that would allow for the
urification of higher numbers of ESC-derived cardiomyo-
ytes. This strategy has been difficult because mouse-derived
SC cardiomyocytes have low mitotic rates (86). A surpris-
ng characteristic of human ESC-derived cardiomyocytes is
hat, unlike their mouse counterparts, they have a high
roliferative capacity (87–89). The advantages of this ca-
acity are multifold. First, it provides a unique human
odel system to analyze the biochemical mechanisms that
ontrol cardiomyocyte proliferation. Initial analyses have
lready shown that the proliferation of these cells can be
egulated by the IGF-1/PI3 kinase/Akt signaling pathway
89). In vivo studies have also shown that grafts of trans-
lanted human ESC-derived cardiomyocytes grow in size
even-fold over a four-week period (11). The elucidation of
he cellular mechanisms that control this process can then
e exploited to expand the cardiomyocyte population before
ransplantation and/or to increase proliferation post-
ransplantation in situ.
LINICAL TRIALS OF CARDIAC REPAIR:
RIMUM NON NOCERE
fter nearly 10 years in preclinical animal models, cell-
ased cardiac repair trials have begun in humans. (For a
etailed review, please see Laflamme and Murry [14] and
urry et al. [90].) The first clinical trials were performed
ith autologous skeletal myoblasts (91), which, by virtue of
eeding several weeks to expand in culture, have all been aerformed in patients with chronic ischemic heart disease.
rials of autologous bone marrow cells began a few years
ater, involving both acute infarction and chronic ischemic
isease (92–95). Most of these have been safety and feasi-
ility trials, neither designed nor powered to provide data on
fficacy, and therefore caution in interpretation is clearly
ndicated at this early stage. Nevertheless, there are tanta-
izing trends toward improved function in most of the
ell-treated hearts that are supported by the findings of early
andomized, controlled trials (96,97).
The editors of the Journal of the American College of
ardiology charged us to address the following questions
bout current cardiac repair trials: 1) Should stem cell trials
e in the clinic? 2) If so, for acute infarction or chronic
schemic disease? 3) What are the optimal cells? 4) Which
utcomes should we be looking for?
These are lucid and relevant questions but, unfortunately,
e do not have enough information to answer all of them.
t is our opinion that clinical trials of cell-based cardiac
epair are warranted, based on a large volume of data
howing preclinical safety and efficacy. Animal models,
lthough critical, cannot reproduce all aspects of human
eart disease. Conversely, once safety and efficacy have been
stablished in the animal, it is reasonable to move carefully
o the clinic while the underlying mechanism is being
stablished.
The optimal timing of cell-based therapy after myocardial
nfarction is currently unknown. A recent infarct still in the
ealing phase is almost surely a more favorable substrate for
ell-based repair than is an old scar within a dilated
entricle. On the other hand, many patients with infarcts do
ell with standard treatment and may not need such an
dvanced intervention as cell-based therapy. An improved
bility to predict which patients will progress to heart failure
ould help in this regard. We think the current approach of
esting both acute and chronic ischemic disease (as well as
ilated cardiomyopathy) is reasonable, given our current
nformation.
Current evidence does not permit one to rationally choose
he best cell for cardiac repair. Autologous cells with limited
lasticity, such as skeletal muscle or bone marrow, are likely
o be the safest populations for initial trials. This is
articularly true if one is studying patients with recent
nfarcts, for whom standard treatment is reasonably effec-
ive. On the other hand, more potent stem cells, such as
mbryonic stem cells, offer greater opportunities to truly
egenerate myocardium. However, stem cell potency is a
ouble-edged sword, and as highly potent cells are explored
linically, risks for complications such as arrhythmias and
he formation of tumors may increase. For highly potent
ells, it may be prudent to begin in patients targeted for
eart transplantation, for instance, implanting cells at the
ime of left ventricular assist device placement. Patients on
eft ventricular assist devices should be least affected by
rrhythmias or cardiac tumors, and cardiectomy at the time
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Stem Cells and Cardiac Repair May 2, 2006:1777–85f transplantation should prove a definitive therapy should a
eratoma appear.
We believe that cardiac repair trials need to focus on
entricular function and anatomy as primary end points.
lthough these measurements are less powerful than mor-
idity and mortality, the field is not sufficiently advanced to
upport such outcome-based end points. If we are able to
eliably demonstrate that cardiac repair works to improve
jection fraction and prevent/reverse ventricular dilation, we
hen can begin to test whether morbidity and mortality are
educed. Because the mechanism through which cell therapy
cts is still being characterized, clinical trials that establish
echanistic correlates will be most helpful. For example,
tudies using magnetic resonance imaging in patients suggest
hat cell therapy might alter the rate of infarct repair or
nfluence the amount of scar contraction (93). Positron emis-
ion tomography studies have demonstrated increased glu-
ose uptake and enhanced myocardial blood flow in cell-
ngrafted regions (94,95,98), which provide important
nformation regarding effects on tissue metabolism and
erfusion. Another very useful mechanistic end point for
linical trials is the ability to track cells after they are
mplanted, for instance, through use of paramagnetic par-
icles visible by magnetic resonance imaging (99), positron-
mitting isotopes (100), or molecular tracers (101). Finally,
e believe that, whenever possible, tissue-based analyses
hould be included in clinical trial design, either by evalu-
tion of explanted hearts at the time of transplantation (102)
r by autopsy of patients who die following cell therapy
103).
HINKING STRAIGHT ABOUT STEM CELL RESEARCH
t is important to evaluate all studies of cardiac regeneration
ith a critical mind, and studies claiming great advances
erit particularly careful scrutiny. One need not have detailed
raining in stem cell biology to formulate reasonable opinions.
hen evaluating a new study, the first thing the reader should
o is identify how the authors tracked the cells’ lineage (who
egat whom) and the cells’ phenotype (what were the cells at
he beginning, what were they at the end). As stressed
reviously, stem cell studies are only as good as their ability
o track these two parameters. After that, it is sufficient to
se common sense and remember the fundamentals of
xperimental design. For example, we must never underes-
imate the importance of control experiments. Most of us
ave read articles in which readers are whisked down a path
hat involves only stem cell treatments, leaving us to infer
hat might have happened in control animals. Controls do
ot always do what we predict, which is exactly what makes
hem so important. Another critical facet of regenerative
herapy, too often omitted, is blinding of the observers.
hen one experimental outcome leads to publication,
peaking invitations and research funding, and the alternate
utcome leads only to more toil, it is imperative to protect
urselves even from subconscious biases. We submit that alltem cell therapy studies need to have their end points read
y blinded observers, with the code broken at the study’s
nd.
The early phases of research in cardiac repair used histolog-
cal outcomes as their principal guide, which provided good
nsights into the fates of transplanted cells but told little
bout effects on contractile function. During the last five
ears, however, there has been a pronounced shift toward
hysiological outcomes as principal end points. This shift is
easonable—patients care more about their heart’s function
han they do its histology. However, the shift toward
hysiology has made mechanisms less evident, and multiple
eports have erroneously reasoned that, because ventricular
unction was improved, the heart was regenerated. Follow-
ng this line of logic, one might also conclude that beta-
drenergic blockers and angiotensin-converting enzyme in-
ibitors regenerate the heart. Both drugs reduce remodeling
nd improve ventricular function after an infarct, but few
ould assert that this is achieved through regeneration. As
e read the existing literature, it is important to bear in
ind that many paths lead to improved function, and not all
roceed through regeneration.
LOSING THOUGHTS
tem cells offer the chance to rebuild damaged tissues like
he infarcted heart from their component parts. What was a
adical notion 10 years ago is now a mainstream experimen-
al concept, and early clinical trials are underway throughout
he world. The scientific and lay communities are extremely
nthusiastic about the promise this field offers. For research-
rs in the field, however, enthusiasm is not enough. We
ust be rigorous, skeptical, and willing to have our own
ork subjected to public scrutiny and criticism. Our inter-
entions have to be understood mechanistically (to permit
ational improvement), tested in the best animal models
including large animals whenever possible), and reproduced
y independent groups before they move to the clinic. The
igh expectations for stem cell research are reminiscent of
he gene therapy field a decade ago, where an overzealous
ush to the clinic resulted in an adverse clinical outcome and
marked setback to the field (104). Stem cell therapy must
ot repeat gene therapy’s trajectory. If we do it right,
owever, stem cells may give us the tools to reactivate
rocesses of embryological development in diseased tissues.
f so, the potential benefit to human health will be great.
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